Mihaljević, V.; Zjalić, M.; Kizivat, T.; Omanović Kolarić, T.; Smolić, M.; Rođak, E.; Čović, M.; Kuna, L.; Smolić, R.; Včev, A.;
et al. Molecular Mechanisms Linking Empagliflozin to Renal Protection in the LLC-PK1 Model of Diabetic Nephropathy. Biomedicines 2022, 10, 2983.
https://doi.org/10.3390/biomedicines10112983
AMA Style
Mihaljević V, Zjalić M, Kizivat T, Omanović Kolarić T, Smolić M, Rođak E, Čović M, Kuna L, Smolić R, Včev A,
et al. Molecular Mechanisms Linking Empagliflozin to Renal Protection in the LLC-PK1 Model of Diabetic Nephropathy. Biomedicines. 2022; 10(11):2983.
https://doi.org/10.3390/biomedicines10112983
Chicago/Turabian Style
Mihaljević, Vjera, Milorad Zjalić, Tomislav Kizivat, Tea Omanović Kolarić, Martina Smolić, Edi Rođak, Marina Čović, Lucija Kuna, Robert Smolić, Aleksandar Včev,
and et al. 2022. "Molecular Mechanisms Linking Empagliflozin to Renal Protection in the LLC-PK1 Model of Diabetic Nephropathy" Biomedicines 10, no. 11: 2983.
https://doi.org/10.3390/biomedicines10112983
APA Style
Mihaljević, V., Zjalić, M., Kizivat, T., Omanović Kolarić, T., Smolić, M., Rođak, E., Čović, M., Kuna, L., Smolić, R., Včev, A., & Bilić Ćurčić, I.
(2022). Molecular Mechanisms Linking Empagliflozin to Renal Protection in the LLC-PK1 Model of Diabetic Nephropathy. Biomedicines, 10(11), 2983.
https://doi.org/10.3390/biomedicines10112983